Digital Commons Network^™

Do Pcsk9 Monoclonal Antibodies Plus Soc Prevent Major Adverse Cardiovascular Events In Adults With Hypercholesterolemia Compared To Placebo Plus Soc?, Amy Doyle

PCOM Physician Assistant Studies Student Scholarship

Objective: The objective of this selective EBM review is to determine whether or not PCSK9 monoclonal antibodies plus SOC prevent major adverse cardiovascular events in adults with hypercholesterolemia compared to placebo plus SOC.

Study Design: This review is using one double-blinded randomized controlled trial (RCT) and two open-label RCTs investigating alirocumab and evolocumab, published in 2014 and 2015.

Data sources: Articles were found on PubMed, and were published in peer-reviewed journals in English.

Outcome Measured: The outcome measured was major adverse cardiac events (MACE), which included death, MI, hospitalization for unstable angina, revascularization, or cerebrovascular event. …